This age-group, between 40–50 years, is an important age group of interest, as many molecular and neuronal changes are manifested, ranging from hippocampal atrophy to increased amyloid-beta and tau protein accumulation26–28, that may set the stage for future cognitive decline. The gene discussed is MAPT; the disease is hippocampal atrophy.